Pierre Fabry forges I/O discovery pact; Actinium surges on CHMP support
→ France’s Pierre Fabre struck a deal with H-Immune SAS to develop new immunotherapies, utilizing H-Immune’s technology platform to generate lead candidates of fully human antibodies to serve as the initial step in a program to develop immuno-oncology therapeutics. “This transaction strengthens Pierre Fabre’s position in the areas of immuno-oncology and novel cutting-edge biotherapeutics,” said Laurent Audoly, head of R&D of Pierre Fabre Pharmaceuticals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.